Cargando…
Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia
Male lower urinary tract symptoms (LUTS) is an increasingly important problem for the majority of late middle aged and elderly men. Fexapotide triflutate (FT) is a first in-class compound given by local injection via the transrectal intraprostatic route under ultrasound guidance. Data from >1700...
Autores principales: | Shore, Neal, Tutrone, Ronald, Roehrborn, Claus G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348527/ https://www.ncbi.nlm.nih.gov/pubmed/30719081 http://dx.doi.org/10.1177/1756287218820807 |
Ejemplares similares
-
Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results
por: Shore, Neal, et al.
Publicado: (2020) -
Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement
por: Shore, Neal, et al.
Publicado: (2018) -
Fexapotide Triflutate Induces Selective Prostate Glandular Pharmaco-Ablation in the Rat
por: Averback, Paul, et al.
Publicado: (2019) -
Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis
por: Wei, Yifan, et al.
Publicado: (2022) -
A Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic Hyperplasia
por: Shore, Neal
Publicado: (2015)